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Diabetes mellitus and COVID-19:  
factors associated with bad prognosis 
ABSTRACT
Diabetes is a risk factor for bad prognosis of COVID-19. 
Many mechanisms can explain the bad prognosis of 
COVID-19 in diabetics, but they remain hypothetical. 
The high prevalence of diabetes on the African conti-
nent, particularly in North Africa (12.2%), constitutes 
a threat of increased morbidity and mortality linked 
to COVID-19. We must pay particular attention to this 
fragile population, with more time and resources, 
especially for the elderly, obese or those with chronic 
complications of diabetes who have a high risk of 
developing severe forms. (Clin Diabetol 2020; 9; X 
XXX–XXX)
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New pneumonia caused by a new coronavirus 
named SARS-CoV-2 appeared in China at the end of 
2019 and quickly spread around the world (it ap-
proaches 5 million cases in 188 countries at the time 
of writing of this letter). The case fatality rate varied 
so much internationally, In China it was between 1 
and 2%, in Europe it was around 9% in some coun-
tries and in Africa it is 3.2%. This disparity in rates is 
explained by the quality of screening and the nature of 
the population. We have noticed in Morocco, that the 
lethality rate went down from 7% in April to 2.7% in 
May, this decrease was proportional to the increase in 
the number of screening tests per day. In the literature, 
the most distinctive comorbidities related to a poor 
prognosis of COVID-19 pneumonia are cardiovascular 
(hypertension and ischemic heart disease), metabolic 
(diabetes, obesity), chronic or respiratory renal diseases 
[1]. Table 1 summarizes the main comorbidities associ-
ated with COVID-19 infection in Italy [2]. 
Diabetes is one of the most common comorbidi-
ties in infected patients, the second in China and Italy 
following hypertension [2–4]. Data from China have 
reported an increased incidence of COVID-19 in diabet-
ics [1, 2]. However, a recent meta-analysis of 12 studies 
including a total of 2,108 Chinese patients concluded 
that diabetes paradoxically does not increase the risk 
of infection by the virus [5]. Regarding the impact of 
diabetes on the prognosis of the disease, only 6 of 12 
Chinese studies have been able to provide information, 
and they confirmed that diabetes should be considered 
as a risk factor for a rapid progression and bad progno-
sis of COVID-19 [5]. Similarly, based on data from the 
Chinese center for disease control including more than 
44,000 confirmed cases, the fatality rate was multiplied 
by 3 in the presence of diabetes (2.3% vs. 7.3%) [5]. 
In virology, this finding is not new, it has already been 
reported for other respiratory viral infections including 
seasonal flu, influenza A (H1N1) in 2009 and the two 
previous COVID infections: SARS in 2002 and MERS in 
2012 [6, 7]. A recent French observational study was 
the first to focus on the predictors of severe forms 
in hospitalized diabetic patients; they were similar 
to those found in the non-diabetic population, such 
as age and obesity, but adding that the presence of 
complications of diabetes was positively associated 
with death. Insulin (the agent of choice to control 
glycaemia in hospitalized patients with COVID-19), 
like antihypertensive medications that interact with 
the renin-angiotensin-aldosterone system, is not a risk 
factor for severe form of COVID-19 [8].
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Many mechanisms can explain the bad prognosis 
of COVID-19 in diabetics, but they remain hypothetical, 
several factors have been mentioned in the literature:
 — type 2 diabetes, often associated with obesity 
predisposes to a pro-inflammatory state via in-
creased inflammatory mediators interleukin 6 
(IL-6) and tumor necrosis factor a (TNF-a), which 
might facilitate the cytokine storms, which in turn 
appears to be the cause of the severe cases of 
COVID-19 pneumonias and of death in many pa-
tients;
 — high mortality rate in the presence of chronic 
complications of diabetes, particularly macrovas-
cular ones, was raised in Chines series and con-
firmed in the French study [8, 9];
 — inflammation increases insulin resistance and the 
need for insulin, which affects glucoregulation 
and increases the risk of ketoacidosis. On the oth-
er hand SARS-CoV-2 could directly damage beta 
cells, this hypothesis has been raised to explain 
the large number of new cases of diabetes and 
also the need for high doses of insulin in infect-
ed patients. Indeed pancreatic beta cells express 
also the ACE2 receptor (the coronavirus binding 
site), such as lung, heart and kidney cells [3]. This 
hypothesis suggests screening for diabetes in pa-
tients with COVID-19 infection;
 — hypercoagulability appears also to be the cause 
of the severe cases of COVID-19 pneumonias. It 
is known that diabetes is associated with hyper-
coagulability and endothelial dysfunction which 
is only partially corrected by optimal glycemic 
control. In addition the association with a pro-
coagulant infection by the cytokine storms will 
increase hypercoagulability, this explains why 
the level of D-dimer was significantly higher in 
diabetic patients infected with the coronavirus in 
several series [9, 10]. Conversely, hypoglycemia 
increases also the inflammatory state and platelet 
reactivity, this is why strict glycemic control dur-
ing coronavirus infection could be deleterious. So 
rigorous monitoring of capillary blood glucose 
and therapeutic adaptations are strongly recom-
mended, especially in the case of treatment with 
hydroxychloroquine. The latter, with an unknown 
hypoglycemic action, is approved by most African 
medical societies for the treatment of SARS-CoV-2 
in combination with azithromycin;
 — finally, an even more worrying aspect of the in-
teraction of two pandemics, is the asymptomatic 
character in the initial phase of the infection 
which was noted in the Chinese’s series, with less 
fever, chills and shortness of breath. This could 
be responsible for a delay in treatment and an 
increase in the incidence of severe forms [9].
Conclusion
In the light of these findings and the high preva-
lence of diabetes on the African continent, particularly 
in North Africa (12.2%), there is a threat of increased in-
cidence of morbidity and mortality linked to COVID-19. 
In addition to chronic complications, the pneumonia 
caused by COVID-19 worsens the prognosis of our 
diabetic patients. We must pay particular attention to 
this fragile population, with more time and resources, 
especially for the elderly, obese or those with chronic 
complications of diabetes who have a high risk of devel-
oping severe forms. Without forgetting that COVID-19 
infection is an opportunity to screen for diabetes. The 
future research will explain the behavior of COVID-19 
in patients with diabetes.
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Table 1. Main comorbidities associated with COVID-19 
infection in Italy [2]
Type of comorbidity (%)
Hypertension 73.8
Diabetes mellitus 33.9
Ischemic heart disease 30.1
Atrial fibrillation 22.0
Chronic renal failure 20.2
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